

2725-8275

The Development of Iron Chelators for Clinical Use

Edited by

Raymond J. Bergeron

Graduate Research Professor

Department of Medicinal Chemistry

University of Florida

Gainesville, Florida

Gary M. Brittenham

Professor of Medicine

Division of Hematology

MetroHealth Medical Center

Case Western Reserve University

Cleveland, Ohio



CRC Press

Boca Raton Ann Arbor London Tokyo

TABLE OF CONTENTS

Chapter 1	
Physiology and Pathophysiology of Iron Metabolism: Implications for Iron Chelation Therapy in Iron Overload	1
P. Ponka	
Chapter 2	
Iron, Oxidative Damage, and Chelating Agents	33
B. Halliwell	
Chapter 3	
Iron Chelation Therapy in the Treatment of Iron Overload	57
M. J. Pippard	
Chapter 4	
Potential Clinical Applications of Iron Chelating Therapy	75
C. Hershko, G. Link, M. Tzahor, and A. Pinson	
Chapter 5	
Iron Withholding: The Natural Defense System and Its Modification by Pharmacologic Agents	97
E. D. Weinberg	
Chapter 6	
Iron Chelation as a Chemotherapeutic Strategy in the Treatment of Malaria	111
V. R. Gordeuk, G. M. Brittenham, and P. E. Thuma	
Chapter 7	
Toward Better Chelation Therapy: Current Concepts and Research Strategy	131
H. P. Schnebli, I. Hassan, K. O. Hamilton, S. Lynch, Y. Jin, H. P. Nick, H. H. Peter, U. Junker Walker, R. Ziel, S. C. Khanna, R. Dean, and R. J. Bergeron	
Chapter 8	
Siderophores as Biological Deferration Agents and the Regulation of Their Synthesis by Iron	151
J. B. Neilands	

Chapter 9	
Biochemical and Genetic Studies on Lysine: <i>N</i> ⁶ -Hydroxylase Involved in Aerobactin Synthesis	169
A. M. Thariath, M. A. Valvano, and T. Viswanatha	
Chapter 10	
The Ferrichrome Biosynthetic Pathway of <i>Ustilago maydis</i> Reveals Similarities to the Aerobactin Pathway of <i>Escherichia coli</i> and to Globin Gene Regulation in Erythroid Cells	187
S. A. Leong, B. Mei, C. Voisard, A. Budde, J. McEvoy, J. Wang, P. Xu, and B. Saville	
Chapter 11	
Ability of Catecholate Derivatives to Promote Growth of Gram-Negative Bacteria	209
R. Reissbrodt and W. Rabsch	
Chapter 12	
Synthesis and Biological Activity of Hydroxamate-Based Iron Chelators	237
R. J. Bergeron and J. S. McManis	
Chapter 13	
Siderophore-Mediated Drug Delivery: The Design, Synthesis, and Study of Siderophore-Antibiotic and Antifungal Conjugates	275
M. J. Miller and F. Malouin	
Chapter 14	
Siderophore-Based Hydroxypyridonate Sequestering Agents	307
K. N. Raymond and J. Xu	
Chapter 15	
Ligand Design of Chelating Agents Effective in the Coordination of Fe(III) and for the Removal of Iron in Cases of Iron Overload . . .	329
A. E. Martell, R. J. Motekaitis, Y. Sun, and E. T. Clarke	
Chapter 16	
The Design of Therapeutically Useful Iron Chelators	353
R. C. Hider, J. B. Porter, and S. Singh	
Chapter 17	
A Comparative Evaluation of Iron Chelators in a Primate Model . . .	373
H. H. Peter, R. J. Bergeron, R. R. Streiff, and J. Wiegand	

Chapter 18

Preliminary Results from a Phase I Clinical Trial of HBED395

R. W. Grady, A. D. Salbe, M. W. Hilgartner, and P. J. Giardina